The European FGM market comprises the FGM reader segment and the FGM sensor segment. The business model for FGM is similar to traditional blood glucose meters and CGM, where the reader is the base equipment and the majority of sales are made from the disposable sensor component, which is replaced every 14 days. However, due to a recent product update that allows patients to use near-field communication (NFC) technology to substitute their smartphones as the reader component, purchase of the reader device is no longer mandatory. As a result, the disposable sensors will be the most important revenue generator for the FGM market as it gains further acceptance and higher uptake in Europe.
The FGM system is made up of two components: a sensor and an electronic reader device that takes readings of glucose levels from the sensor. Sensors are worn on the back of the upper arm of patients for up to 14 days and inserted in a similar fashion as CGM sensors, with an adhesive to hold it in place. The reader component is manually placed over the sensor and after about a second, the reader displays a measurement of the patient’s glucose level, a historical trend of previous scans and the direction in which the glucose level is moving. A recent product update allows patients to use near-field communication (NFC) technology to substitute their smartphones as the reader component, eliminating the need to purchase the dedicated reader device. The FGM system is also factory calibrated which removes the need for routine fingersticks; something that is not available in current CGM systems. These features are popular with patients who cite “the pain, inconvenience and indiscretion” of fingersticking as the primary reasons for not managing their diabetes as efficiently and proactively as they should.
'
TABLE OF CONTENTS I
LIST OF FIGURES IV
LIST OF CHARTS V
EXECUTIVE SUMMARY 1
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
MARKETS INCLUDED 9
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
1.1 RESEARCH SCOPE 11
1.2 IDATA’S 9-STEP METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 13
Step 3: Preparation for Interviews & Questionnaire Design 14
Step 4: Performing Primary Research 15
Step 5: Research Analysis: Establishing Baseline Estimates 17
Step 6: Market Forecast and Analysis 18
Step 7: Identify Strategic Opportunities 20
Step 8: Final Review and Market Release 21
Step 9: Customer Feedback and Market Monitoring 22
DISEASE OVERVIEW 23
2.1 INTRODUCTION 23
2.1.1 Types of Diabetes 23
2.1.2 Diabetes Complications 25
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 27
2.1.4 Signs and Symptoms 28
2.1.5 Diabetes Monitoring 29
2.1.6 Treatment 31
2.1.7 Drug Delivery Systems 33
COUNTRY PROFILES 35
3.1 INTRODUCTION 35
3.1.1.1 Population 35
3.1.1.2 GDP Per Capita 35
3.1.1.3 Units 35
3.2 GERMANY 36
3.3 FRANCE 37
3.4 UNITED KINGDOM 38
3.5 ITALY 39
3.6 SPAIN 40
3.7 BENELUX 41
3.8 SCANDINAVIA 42
3.9 AUSTRIA 43
3.10 SWITZERLAND 44
3.11 PORTUGAL 45
FLASH GLUCOSE MONITORING MARKET 46
4.1 INTRODUCTION 46
4.2 MARKET OVERVIEW 48
4.3 MARKET ANALYSIS AND FORECAST 52
4.3.1 Total FGM Market 52
4.3.2 FGM System Market 54
4.3.3 FGM Sensor Market 56
4.4 DRIVERS AND LIMITERS 58
4.4.1 Market Drivers 58
4.4.2 Market Limiters 58
4.5 COMPETITIVE MARKET SHARE ANALYSIS 60
ABBREVIATIONS 63
Chart 1 1: Diabetes Diagnosis, Treatment and Drug Delivery, Europe, 2012 – 2022 3
Chart 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Market Overview, Europe, 2012 & 2022 3
Chart 3 1: Country Profile, Germany, 2015 36
Chart 3 2: Country Profile, France, 2015 37
Chart 3 3: Country Profile, United Kingdom, 2015 38
Chart 3 4: Country Profile, Italy, 2015 39
Chart 3 5: Country Profile, Spain, 2015 40
Chart 3 6: Country Profile, Benelux, 2015 41
Chart 3 7: Country Profile, Scandinavia, 2015 42
Chart 3 8: Country Profile, Austria, 2015 43
Chart 3 9: Country Profile, Switzerland, 2015 44
Chart 3 10: Country Profile, Portugal, 2015 45
Chart 4 1: Total FGM Market by Segment, Europe, 2015 50
Chart 4 2: Total FGM Market Breakdown, Europe, 2022 51
Chart 4 3: Total FGM Market Breakdown, Europe, 2022 51
Chart 4 4: Total FGM Market, Europe, 2012 – 2022 (€M) 53
Chart 4 5: FGM System Market, Europe, 2012 – 2022 55
Chart 4 6: FGM Sensor Market, Europe, 2012 – 2022 57
Chart 4 7: Leading Competitors, FGM Market, Europe, 2015 62
Novo Nordisk
Sanofi
Roche
Johnson & Johnson
Eli Lilly
Abbott
Ascensia
Becton Dickinson
Medtronic
Menarini
DexCom
Ypsomed
Insulet
Artsana
B. Braun
Terumo
Others include: Abbott, AgaMatrix, Artsana, Apollo, BBI Healthcare, B. Braun, Berger, Beurer, Boehringer Ingelheim, Cellnovo, Codan, Comfort Point, Dario Health, Elektronika, Entra Health Systems, GlucoRx, GlucoZen, Infopia, Medtronic, MED TRUST, Medisana, Menarini, Merck Serono, MSP bodmann, Neon Diagnostics, NordicInfu Care, Novalab Ibérica, Novico, Owen Mumford, Pentaferte, Roche, Sanofi, SD BIOSENSOR, SFM Medical, Smiths Medical, Spirit Healthcare, Sooil, Trividia Health, Ypsomed, etc.
